BriaCell Therapeutics Corp.(BCTX)Earnings, Financials & Key Ratios
BCTX•NASDAQ
$4.10
$5M mkt cap·Price updated May 7, 2026
AboutBriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.Show more
- Revenue$0
- EBITDA-$38M+17.3%
- Net Income-$36M-457.4%
- EPS (Diluted)-86.25-44.5%
- ROE-363.04%
- ROIC-1263.21%
- Interest Coverage-735.71
BCTX Key Insights
BriaCell Therapeutics Corp. (BCTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 14 (bottom 14%)
- ✗Shares diluted 71.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BCTX Price & Volume
BriaCell Therapeutics Corp. (BCTX) stock price & volume — 10-year historical chart
Loading chart...
BCTX Growth Metrics
BriaCell Therapeutics Corp. (BCTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-134.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM48.64%
Return on Capital
10 Years-762.92%
5 Years-151.59%
3 Years-233.64%
Last Year-341.62%
BCTX Peer Comparison
BriaCell Therapeutics Corp. (BCTX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 ADCT | 478.24M | 3.76 | -3.36 | 14.85% | -173.02% | |||
 CRIS | 75.96M | 0.58 | -0.99 | -13.43% | -80.29% | -138.81% | 0.30 | |
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 IOVA | 1.27B | 3.55 | -3.26 | 60.6% | -123.9% | -50.17% | 0.07 | |
 NUVL | 7.53B | 102.40 | -17.50 | -42.78% | ||||
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 |
Compare BCTX vs Peers
BriaCell Therapeutics Corp. (BCTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCTX Income Statement
BriaCell Therapeutics Corp. (BCTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jul'17 | Jul'18 | Jul'19 | Jul'20 | Jul'21 | Jul'22 | Jul'23 | Jul'24 | Jul'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 290 | 16.88K | 18.83K | 18.73K | 19.46K | 19.42K | 20.51K | 114.64K | 147.89K | 148.37K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -289▲ 0% | -16.88K▼ 5739.8% | -18.83K▼ 11.6% | -18.73K▲ 0.5% | -19.46K▼ 3.9% | -19.42K▲ 0.2% | -20.51K▼ 5.6% | -114.64K▼ 459.0% | -147.89K▼ 29.0% | -148.37K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | 83.97% | -5739.79% | -11.59% | 0.52% | -3.88% | 0.23% | -5.62% | -459.02% | -29% | - |
| Operating Expenses | 3.21M | 4.96M | 6.23M | 4.82M | 8.88M | 19.42M | 31.24M | 45.43M | 37.59M | 39.66M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.09M | 1.85M | 1.29M | 1.84M | 6.3M | 9.22M | 10.64M | 8.29M | 5.93M | 7.18M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 2.12M | 3.11M | 4.94M | 2.98M | 2.58M | 10.2M | 20.6M | 37.14M | 29.5M | 31.86M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.15M | 630.01K |
| Operating Income | -3.21M▲ 0% | -4.97M▼ 54.6% | -6.25M▼ 25.8% | -4.84M▲ 22.6% | -8.9M▼ 83.9% | -19.44M▼ 118.4% | -31.26M▼ 60.8% | -45.54M▼ 45.7% | -37.73M▲ 17.2% | -42.71M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -46.55% | -54.65% | -25.76% | 22.62% | -83.95% | -118.43% | -60.78% | -45.71% | 17.15% | - |
| EBITDA | -3.21M | -4.96M | -6.23M | -4.82M | -8.88M | -19.42M | -31.24M | -45.43M | -37.59M | -42.56M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -46.65% | -54.14% | -25.8% | 22.69% | -84.26% | -118.69% | -60.83% | -45.44% | 17.27% | -13.36% |
| D&A (Non-Cash Add-back) | 290 | 16.88K | 18.83K | 18.73K | 19.46K | 19.42K | 20.51K | 114.64K | 147.89K | 148.37K |
| EBIT | -3.22M | -5.39M | -5.79M | -4.91M | -17.53M | -34.13M | -27.27M | -6.74M | -36.78M | -41.91M |
| Net Interest Income | 6.42K | -4.37K | -19.41K | -36.2K | -96.2K | 172.61K | 1.2M | 393.57K | 115.09K | 225.76K |
| Interest Income | 6.42K | 15.97K | 12.06K | 0 | 4.02K | 173.86K | 1.2M | 393.57K | 166.38K | 278.37K |
| Interest Expense | 0 | 20.34K | 31.47K | 36.2K | 100.22K | 1.24K | 0 | 0 | 51.29K | 52.61K |
| Other Income/Expense | -2.48K | -435.76K | 434.77K | -104.51K | -8.73M | -14.69M | 3.99M | 38.81M | 899.71K | 1.07M |
| Pretax Income | -3.22M▲ 0% | -5.41M▼ 68.1% | -5.82M▼ 7.6% | -4.94M▲ 15.0% | -17.63M▼ 256.6% | -34.13M▼ 93.6% | -27.27M▲ 20.1% | -6.74M▲ 75.3% | -36.83M▼ 446.6% | -41.64M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -3.22M▲ 0% | -5.41M▼ 68.1% | -5.82M▼ 7.6% | -4.94M▲ 15.0% | -17.63M▼ 256.6% | -34.13M▼ 93.6% | -27.27M▲ 20.1% | -6.55M▲ 76.0% | -36.5M▼ 457.4% | -38.37M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -44.17% | -68.07% | -7.58% | 15.04% | -256.61% | -93.61% | 20.1% | 75.99% | -457.4% | -134.87% |
| Net Income (Continuing) | -3.22M | -5.41M | -5.82M | -4.94M | -17.63M | -34.13M | -27.27M | -6.74M | -36.83M | -41.64M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -419.97K | -751.79K | -702.63K |
| EPS (Diluted) | -1348.63▲ 0% | -1798.34▼ 33.3% | -1505.30▲ 16.3% | -1038.56▲ 31.0% | -585.01▲ 43.7% | -330.38▲ 43.5% | -261.86▲ 20.7% | -59.69▲ 77.2% | -86.25▼ 44.5% | -13.69▲ 0% |
| EPS Growth % | 0.86% | -33.35% | 16.3% | 31.01% | 43.67% | 43.53% | 20.74% | 77.21% | -44.5% | 48.64% |
| EPS (Basic) | -1348.63 | -1798.34 | -1505.30 | -1038.56 | -585.01 | -330.38 | -261.86 | -59.69 | -86.25 | - |
| Diluted Shares Outstanding | 22.65K | 28.52K | 38.64K | 47.59K | 301.31K | 1.03M | 1.04M | 1.1M | 1.88M | 2.8M |
| Basic Shares Outstanding | 22.65K | 28.52K | 38.64K | 47.59K | 301.31K | 1.03M | 1.04M | 1.1M | 1.88M | 2.8M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BCTX Balance Sheet
BriaCell Therapeutics Corp. (BCTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jul'17 | Jul'18 | Jul'19 | Jul'20 | Jul'21 | Jul'22 | Jul'23 | Jul'24 | Jul'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.63M | 1.88M | 168.53K | 261.46K | 72.23M | 54.31M | 35.99M | 5.07M | 27.4M | 32.18M |
| Cash & Short-Term Investments | 1.62M | 1.75M | 157.03K | 21.25K | 71.57M | 52.63M | 28.38M | 1.2M | 24.56M | 29.9M |
| Cash Only | 1.01M | 720.26K | 157.03K | 21.25K | 71.57M | 52.63M | 28.38M | 1.2M | 14.43M | 29.9M |
| Short-Term Investments | 601.76K | 1.03M | 0 | 0 | 0 | 0 | 0 | 0 | 10.14M | 0 |
| Accounts Receivable | 5.6K | 14.56K | 2.82K | 22.52K | 15.71K | 30.91K | 958.56K | 1.9M | 776.54K | 3.09M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -810.63K |
| Total Non-Current Assets | 1.91K | 407.5K | 276.12K | 260.87K | 306.96K | 295.41K | 287.23K | 3.08M | 2.37M | 1.42M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 538.87K | 408.1K | 251.14K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 274.73K | 276.12K | 260.87K | 306.95K | 295.4K | 287.23K | 277.36K | 253.71K | 176.89K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 580.96K | 720.84K | 2.75M |
| Other Non-Current Assets | 1.9K | 132.76K | 0 | 0 | 0 | 0 | 0 | 1.68M | 986.51K | 3.65M |
| Total Assets | 1.64M▲ 0% | 2.28M▲ 39.7% | 444.66K▼ 80.5% | 522.33K▲ 17.5% | 72.54M▲ 13787.9% | 54.6M▼ 24.7% | 36.28M▼ 33.6% | 8.15M▼ 77.5% | 29.77M▲ 265.1% | 33.59M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | 95.78% | 39.66% | -80.54% | 17.47% | 13787.95% | -24.73% | -33.56% | -77.53% | 265.14% | 575.87% |
| Total Current Liabilities | 885.9K | 1.34M | 1.13M | 3.96M | 695.86K | 1.21M | 2.41M | 10.36M | 5.47M | 3.19M |
| Accounts Payable | 0 | 0 | 0 | 0 | 267.59K | 594.14K | 1.5M | 9.95M | 4.51M | 0 |
| Days Payables Outstanding | - | - | - | - | 5.02K | 11.17K | 26.71K | 31.69K | 11.14K | 6.87K |
| Short-Term Debt | 0 | 1.12M | 322.53K | 249.8K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 506.91K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 379K | 219.28K | 810.79K | 3.71M | 0 | 0 | 0 | 0 | 954.58K | 3.19M |
| Current Ratio | 1.84x | 1.40x | 0.15x | 0.07x | 103.81x | 45.00x | 14.96x | 0.49x | 5.01x | 5.01x |
| Quick Ratio | 1.84x | 1.40x | 0.15x | 0.07x | 103.81x | 45.00x | 14.96x | 0.49x | 5.01x | 5.01x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 155.94K | 37.26M | 40.15M | 38.92M | 1.52M | 464.27K | 195.1K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 32.48K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | -35.63K | 37.23M | 40.15M | 38.92M | 1.52M | 464.27K | 2.07M |
| Total Liabilities | 885.9K | 1.34M | 1.13M | 4.12M | 37.96M | 41.36M | 41.32M | 11.88M | 5.93M | 3.38M |
| Total Debt | 0 | 1.12M | 322.53K | 249.8K | 32.48K | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -1.01M | 400.4K | 165.49K | 228.55K | -71.54M | -52.63M | -28.38M | -1.2M | -14.43M | -29.9M |
| Debt / Equity | - | 1.19x | - | - | 0.00x | - | - | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.70x |
| Interest Coverage | - | -244.39x | -198.70x | -133.64x | -88.81x | -15627.39x | - | - | -735.71x | -796.67x |
| Total Equity | 750.23K▲ 0% | 945.02K▲ 26.0% | -688.66K▼ 172.9% | -3.6M▼ 422.4% | 34.58M▲ 1061.3% | 13.25M▼ 61.7% | -5.04M▼ 138.1% | -3.73M▲ 26.1% | 23.83M▲ 739.4% | 29.51M▲ 0% |
| Equity Growth % | -4.68% | 25.96% | -172.87% | -422.38% | 1061.33% | -61.7% | -138.08% | 26.11% | 739.42% | 1634.55% |
| Book Value per Share | 33.13 | 33.14 | -17.82 | -75.59 | 114.78 | 12.82 | -4.84 | -3.40 | 12.65 | 10.53 |
| Total Shareholders' Equity | 750.23K | 945.02K | -688.66K | -3.6M | 34.58M | 13.25M | -5.04M | -3.31M | 24.58M | 41.93M |
| Common Stock | 5.3M | 7.84M | 11.11M | 12.26M | 68.45M | 84.12M | 92.94M | 100.18M | 139.88M | 158.84M |
| Retained Earnings | -6.68M | -9.74M | -14.75M | -18.17M | -36.42M | -77.4M | -107.71M | -118.61M | -153.65M | -172.49M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -57.91K | -80.98K | -101.18K | -138.68K | -173.32K | -177.86K | -185.22K | -192.52K | 38.36M | 55.57M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -419.97K | -751.79K | -702.63K |
BCTX Cash Flow Statement
BriaCell Therapeutics Corp. (BCTX) cash flow — operating, investing & free cash flow history
| Line item | Jul'17 | Jul'18 | Jul'19 | Jul'20 | Jul'21 | Jul'22 | Jul'23 | Jul'24 | Jul'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.91M | -4.95M | -5.12M | -1.55M | -9.89M | -15.87M | -31.89M | -32.97M | -39.07M | -39.07M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -21.12% | -159.16% | -3.34% | 69.63% | -535.98% | -60.55% | -100.9% | -3.38% | -18.52% | -118.15% |
| Net Income | -3.22M | -5.41M | -5.82M | -4.94M | -17.63M | -34.13M | -27.27M | -6.55M | -36.5M | -38.37M |
| Depreciation & Amortization | 290 | 16.88K | 18.83K | 18.73K | 19.46K | 19.42K | 20.51K | 114.64K | 147.89K | 127.66K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 580.54K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 271.74K | 903.45K | -361.74K | 88.77K | 10.63M | 18.73M | 99.73K | -36.17M | -80.47K | -432.45K |
| Working Capital Changes | 1.03M | -466.68K | 1.04M | 3.28M | -2.91M | -497.54K | -4.74M | 9.64M | -2.65M | -1.91M |
| Change in Receivables | -3.49K | -11.98K | 15.59K | -24.19K | 12.68K | -14.66K | 7.02K | -1M | 1.02M | 149.51K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.39M | 0 |
| Cash from Investing | 149.85K | -590.5K | 1.35M | 0 | 0 | 0 | 0 | -931.67K | -10.61M | -383.88K |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -624.21K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.01M |
| Cash from Financing | 2.89M | 5.29M | 3.01M | 1.44M | 82.92M | -4.76M | 5.31M | 6.04M | 63.04M | 78.12M |
| Debt Issued (Net) | 0 | 1.14M | 0 | 27.59K | -421.52K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | -1000K | 1000K | 1000K | 1000K | 3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -12.93M | -63.52K | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | -29.98K | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.1M▲ 0% | -377.65K▼ 134.4% | -757.22K▼ 100.5% | -170.63K▲ 77.5% | 71.55M▲ 42031.2% | -20.77M▼ 129.0% | -26.25M▼ 26.4% | -28.23M▼ 7.5% | 13.24M▲ 146.9% | 22.8M▲ 0% |
| Free Cash Flow | -1.91M▲ 0% | -4.95M▼ 159.2% | -5.12M▼ 3.3% | -1.55M▲ 69.6% | -9.89M▼ 536.0% | -15.87M▼ 60.5% | -31.89M▼ 100.9% | -33.59M▼ 5.3% | -39.07M▼ 16.3% | -36.98M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -21.12% | -159.16% | -3.34% | 69.63% | -535.98% | -60.55% | -100.9% | -5.33% | -16.32% | -18.93% |
| FCF per Share | -84.41 | -173.70 | -132.48 | -32.67 | -32.82 | -15.37 | -30.63 | -30.62 | -20.74 | -20.74 |
| FCF Conversion (FCF/Net Income) | 0.59x | 0.92x | 0.88x | 0.31x | 0.56x | 0.47x | 1.17x | 5.04x | 1.07x | 0.96x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BCTX Key Ratios
BriaCell Therapeutics Corp. (BCTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -418.57% | -637.98% | -4538.83% | - | -113.77% | -142.7% | -664.9% | - | -363.04% | -193.81% |
| Return on Invested Capital (ROIC) | -1232.55% | -689.81% | -1140.62% | - | - | - | - | - | -1263.21% | -1263.21% |
| Debt / Equity | - | 1.19x | - | - | 0.00x | - | - | - | - | 0.00x |
| Interest Coverage | - | -244.39x | -198.70x | -133.64x | -88.81x | -15627.39x | - | - | -735.71x | -796.67x |
| FCF Conversion | 0.59x | 0.92x | 0.88x | 0.31x | 0.56x | 0.47x | 1.17x | 5.04x | 1.07x | 0.96x |
BCTX Frequently Asked Questions
BriaCell Therapeutics Corp. (BCTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BriaCell Therapeutics Corp. (BCTX) grew revenue by 0.0% over the past year. Growth has been modest.
BriaCell Therapeutics Corp. (BCTX) reported a net loss of $38.4M for fiscal year 2025.
Dividend & Returns
BriaCell Therapeutics Corp. (BCTX) has a return on equity (ROE) of -363.0%. Negative ROE indicates the company is unprofitable.
BriaCell Therapeutics Corp. (BCTX) had negative free cash flow of $37.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More BCTX
BriaCell Therapeutics Corp. (BCTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates